Health News

(Elsevier Health Sciences) In a study published in the April 2009 issue of the Journal of Urology, researchers found that in a subgroup of elderly men, among those who were 75 years old or older and had a PSA below 3 ng/ml, none subsequently died of prostate cancer. The discontinuation of routine PSA screening in these men may not increase the rates of undetected lethal disease, and could avoid potentially unnecessary treatments and reduce diagnostic costs.

Read more

Filed under: General Health News
Tags: cancer, General Health News, Prostate Cancer

Related posts

• Why prostate cancer patients fail hormone deprivation therapy (0)
  (Johns Hopkins Medical Institutions) The hormone deprivation therapy that prostate cancer patients often take gives them only a temporary fix, with tumors usually regaining their hold within a couple of years. Now, researchers at Johns Hopkins have discovered critical differences in the hormone receptors on prostate cancer cells in patients who no longer respond to [...]
  
  
• When should PSA testing be stopped? (0)
  Although widespread Prostate-Specific-Antigen (PSA) testing has undoubtedly decreased prostate cancer mortality, is there a point of diminishing returns? Read more [tags] General Health News [/tags]
  
  
• Washington Week: SGR Patch, Lots of FDA Action (0)
  WASHINGTON (MedPage Today) -- Congress passed three health-related bills this week and FDA panels weighed in on drugs for thyroid and prostate cancer, a fecal incontinence product, and a weight-loss device. Read more [tags] General Health News [/tags]
  
  
• Washington Week: SGR Patch, FDA Action (0)
  WASHINGTON (MedPage Today) -- Congress passed three health-related bills this week and FDA panels weighed in on drugs for thyroid and prostate cancer, a fecal incontinence product, and a weight-loss device. Read more [tags] General Health News [/tags]
  
  
• Washington Week: Alzheimer’s Disease, Prostate Cancer Share Spotlight (0)
  WASHINGTON (MedPage Today) -- An NIH report documenting little progress in Alzheimer's disease and FDA approval of a prostate cancer vaccine were highlights of the week's healthcare action in the nation's capital. Read more [tags] General Health News [/tags]